Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trial And Trial: Bracing For Commercialization Of Cell & Gene Therapies

Executive Summary

As novel cell and gene therapies edge closer to the US market, reimbursement for expensive, long-lasting treatments remains uncertain. AmerisourceBergen Senior VP-Strategy & Commercialization Amy Grogg predicts the first launches will involve many different reimbursement models.

Advertisement

Related Content

Spark's Hemophilia B Gene Therapy SPK9001 Packs A Punch And Saves Big Bucks
Cell And Gene Therapies: Where Few Standard Rules Apply
Novartis Beats CAR-T Competitors To The Pricing Punch With Kymriah Approval
Novartis' CAR-T Poised For The Market After Unanimous FDA Adcomm Review
Novartis' CAR-T CTL019 Back On The Blockbuster Hit List

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099375

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel